All In Biotech

Drug Trial Radar · NCT07780565

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Aug 30, 2029

Study completion Aug 30, 2031

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Carna Biosciences, Inc.
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to find the recommended dose of monzosertib in patients with relapsed/refractory AML and high-risk MDS. The safety and effects of monzosertib will also be studied.

Conditions

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome

Interventions

  • MonzosertibDrug

    Give by mouth

  • PosaconazoleDrug

    Given by mouth

  • IsavuconazoleDrug

    Given by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Adverse Events (AEs).Time frame: Through study completion; an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.